Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs
Reinders, Mattheus Karsien

IMPORTANT NOTE: You are advised to consult the publisher’s version (publisher’s PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher’s PDF, also known as Version of record

Publication date:
2008

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Chapter 1

Scope and objectives
Introduction

Gouty arthritis is among the earliest diseases that have been recognised as a clinical entity. First identified by the Egyptians in 2640 BC, podagra (acute gout occurring in the first metatarsophalangeal joint) was later recognised by Hippocrates in the fifth century BC, who referred to it as ‘the unwalkable disease’. Hippocrates also noted the link between the disease and an intemperate lifestyle, referring to podagra as an ‘arthritis of the rich’, as opposed to rheumatism, an ‘arthritis of the poor’ [1].

In history, gout seems a common disease, and many historic figures were suffering from gout [2-9]. Factors that might increase gout incidence back then, were lead contamination of water and a “bourgondic” lifestyle. In 1679, Van Leeuwenhoek observed microscopic gouty crystals. These crystals result from urate deposition in tissues in presence of hyperuricemia. They induce episodic arthritis, which initially are infrequent, usually affecting the foot, and respond well to anti-inflammatory medications such as colchicine and non-steroidal anti-inflammatory drugs. However, these measures do not stop urate deposition from progressing. More frequent and widespread attacks may develop, with increasing resistance to anti-inflammatory therapy. Permanent joint damage may result from gouty erosions, and tophi formation may be complicated by ulcerations and sepsis. Thus, optimal management requires timely introduction of antihyperuricemic therapy to provide a gradient for resorption of the crystals [10].

In the 1950s-1970s, several antihyperuricemic drugs became available for treatment of gout, such as allopurinol, benzbromarone, and probenecid. Allopurinol acts by inhibiting xanthine oxidase, thereby preventing formation of urate (uric acid). Benzbromarone and probenecid act by enhancing the renal excretion of urate. However, a lack of information exists on the risk-benefit ratios of these drugs for the treatment of gout [11]. In a meta-analysis published in 2006, only one randomised controlled trial of good quality assessing antihyperuricemic drugs was found [11].

In 2003, benzbromarone was withdrawn from the global market because of reports of severe hepatotoxicity [12]. In 2004, it returned in The Netherlands (and Spain), but its use was restricted to patients allergic to allopurinol. Recently, reports state that allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrosis [13].

No consensus exists to what extent sUr should be lowered. For instance, the recent European recommendations use a target sUr concentration of 0.36 mmol/l (6.1 mg/dl), the recent British guideline uses 0.30 mmol/l, and the Dutch practitioners standard uses 0.38 mmol/l [14-16]. It is sometimes believed that values below the threshold of monosodium urate at body temperature (37 °C), 0.41 mmol/l are good enough. However, gout symptoms usually occur in the extremities where body temperature is lower than in the centre, and therefore solubility of monosodium urate is lower than 0.41 mmol/l [17]. In addition, solubility of monosodium urate in synovial fluid is influenced by other factors, like pH, concentration of cations, level of articular dehydration, and the presence of such nucleating agents as non-aggregated proteoglycans, insoluble collagens, and chondroitin sulphate [18].
From prospective observational and retrospective data, a strict control of sUr is necessary to successfully diminish tophi and prevent recurrent gout attacks [19-23]. Numerous publications identify that gout management is often sub-optimal, despite detailed understanding of the pathogenesis and pathophysiology of the disorder, the ability to establish the diagnosis with certainty, and the expected effectiveness of lifestyle and pharmacological interventions. Barriers to successful gout management include diagnostic inaccuracy, a paucity of guidelines, sub-optimal patient education and patient adherence, co-morbidities and drug-drug interferences that complicate treatment of gout, and limited urate-lowering alternatives [24].

**Objective of the thesis**

The objective of this thesis is to study the pharmacological and clinical aspects of antihyperuricemic drugs in the treatment of gout in clinical practice, with the focus on efficacy and tolerability.

**Outline of the thesis**

This thesis comprises of four parts: (1) management of gout, (2) outcome research with antihyperuricemic drugs, (3) therapeutic drug monitoring of allopurinol, and (4) rasburicase for treatment of gout.

**References**


